Comparison · NCT00690378-aef90f2f
NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome in ME Patients at the LFU Visit
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NXL104/CAZ vs Imipenem Cilastatin: Microbiological Outcome in ME Patients at the LFU Visit. Trial comparisons, record NCT00690378-aef90f2f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00690378-aef90f2f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.577 | 0.389 | 0.745 | wilson | |
| Risk in group 2 | 0.6 | 0.423 | 0.754 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0231 | -0.266 | 0.221 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.962 | 0.619 | 1.49 | log | |
| Odds ratio, group 1 over group 2 | 0.909 | 0.313 | 2.64 | log | |
| Number needed to treat, for one fewer participant with the outcome on NXL104/CAZ than on Imipenem Cilastatin | 43.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NXL104/CAZ | NXL104 125mg/Ceftazidime 500mg TID | 15 | 26 | OG000 |
| Group 2 | Imipenem Cilastatin | Imipenem cilastatin 500mg 4xdaily | 18 | 30 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Microbiological Outcome in ME Patients at the LFU Visit
- Description
- Sustained eradication: a uropathogen found at entry at \>10\^5 CFU/mL remained \<10\^4 CFU/mL
- Time frame
- 4 to 6 weeks post-therapy
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
- NCT number
- NCT00690378
- Phases
- PHASE2
- Conditions
- Complicated Urinary Tract Infection
- Interventions
- NXL104/ceftazidime, Imipenem/Cilastatin
- Lead sponsor
- Pfizer
- Results first posted
- 2018-05-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00690378?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00690378-aef90f2f